President Donald Trump's new health care initiative aims to reduce prescription drug costs by targeting pharmacy benefit managers, commonly known as PBMs.

Industry executives feel that the direct-to-government sales could open new channels, giving generic manufacturers some ...

A French government working group recommended a sweeping plan to publicize study data and issue guidelines for reporting ...

Tucked inside Trump's drug-pricing executive order is an apparent threat to withdraw drugmakers' medicines if they do not ...

By Andrew Silver SHANGHAI (Reuters) -German healthcare and materials group Merck KGaA has dropped a surcharge on life ...

On May 12th the president signed an executive order that seeks to force drugmakers to reduce their prices in America to align ...

SHANGHAI (Reuters) -Australia will "not compromise" on its policy to subsidise the cost of some medicines, the government ...

The Unified Patent Court (UPC) has quickly become an important forum for pharmaceutical and biotech patent disputes in Europe ...

Discover top income-generating picks inspired by Berkshire Hathaway. Learn how to achieve financial independence with yields ...

The world’s two largest economies, US and China, have temporarily agreed to lower tariffs for each other’s goods, after trade ...

President Donald Trump has signed a sweeping executive order to cut US prescription drug prices by up to 80%, aligning costs ...

Michael Lämmerhofer from the Institute of Pharmaceutical Sciences, University of Tübingen, Germany, spoke to JFK Huber ...